← Leaderboards
Edward Wu
National Center For Advancing Translational Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Center For Advancing Translational Sciences
Same institution · by research overlap
Others in their field
Top investigators on “United States National Institutes Of Health”
- Leonard Freedman · Leidos Biomedical Research, Inc.$816,847,401
- Sonia M Thomas · Research Triangle Institute$701,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$642,073,624
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$513,687,120
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United States National Institutes Of HealthNational Center For Advancing Translational SciencesAccelerationOpioid EpidemicHelping To End Addiction Long-TermPainAffectOpioid Use DisorderPharmaceutical PreparationsPlayPreclinical DevelopmentManufactureSafetyLeadClinical TrialsCollaborationsNovel Therapeutic InterventionIn VivoInvestigational New Drug ApplicationAntagonistNovel TherapeuticsOpioidPainful NeuropathyFirst-In-Human
Grant awards (11)
Targeting Endosomal GPCR (eGPCR) Signaling Platforms for the Treatment of Chronic Pain$1,307,330
ZIA · FY2025 · TR · contact PI
Development of a Non-Paralyzing BoNT-based Biopharmaceutical for the Treatment of Neuropathic Pain$1,307,330
ZIA · FY2025 · TR · contact PI
Development of D3 Antagonist for Substance Use Disorder$1,307,330
ZIA · FY2025 · TR · contact PI
Assay Development to Predict Toxicity of Antisense Oligonucleotide (ASO) Therapeutic Candidates for Rare Diseases$617,657
ZIA · FY2025 · TR · contact PI
Repositioning Basimglurant to Treat Hermansky-Pudlak Syndrome Pulmonary Fibrosis$541,469
ZIA · FY2025 · TR · contact PI
Development of an Antisense Oligonucleotide (ASO) Delivery Platform for Rare Diseases$327,995
ZIA · FY2025 · TR · contact PI
Development of Q203 (Telacebec) for the Treatment of Tuberculosis and Related Mycobacterial Infections$243,622
ZIA · FY2025 · TR · contact PI
Development of a Robust Bioprocess to Rapidly Produce Griffithsin, a Broad-Spectrum Therapeutic and Preventive Antiviral Candidate$75,000
ZIA · FY2025 · TR · contact PI
Development of D3 Antagonist for Substance Use Disorder$4,016,943
ZIA · FY2024 · TR · contact PI
Development of a Non-Paralyzing BoNT-based Biopharmaceutical for the Treatment of Neuropathic Pain$1,874,696
ZIA · FY2024 · TR · contact PI
Targeting Endosomal GPCR (eGPCR) Signaling Platforms for the Treatment of Chronic Pain$1,874,696
ZIA · FY2024 · TR · contact PI